

**Correction**

Schmieder *et al.*: Additional Antiproteinuric Effect of Ultra-high Dose Candesartan: A Double-Blind, Randomized, Prospective Study. *J Am Soc Nephrol* 16: 3038–3045, 2005.

The authors regretfully report an error in quoting the findings of the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria 2 (IRMA 2) Study at the bottom of the left column on page 3043. The second sentence of the paragraph beginning, “Various clinical studies support. . .,” should read as follows:

The largest trial in patients with type 2 diabetes and microalbuminuria, the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria 2 (IRMA 2) Study, found that progression of diabetic nephropathy occurred in approximately 5% of patients who had diabetes and received a high dose of ARB (irbesartan 300 mg/day): In 10% of those who received a low

dose of ARB (irbesartan 150 mg/day) and in 15% of the control group who received placebo on top of other antihypertensive medication (32).

**Correction**

Wahab *et al.*: Connective Tissue Growth Factor CCN2 Interacts with and Activates the Tyrosine Kinase Receptor TrkA. *J Am Soc Nephrol* 16: 340–351, 2005.

In this article, Figure 5 is in fact a duplicate of Figure 12. Please see the correct Figure 5 below. The legend for Figure 5 is correct as published. The publisher regrets this error.

Also in this article, the authors would like to correct a reference to Figure 13. On page 347, in the second line from the top of the right column, the textual reference to Figure 11 should refer instead to Figure 13. The authors regret this error.

